• Explore /
  • Poster
  • / Outcomes and prognostic factors of first-line combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in <i>TFE3</i>-rearranged renal cell carcinoma.

Outcomes and prognostic factors of first-line combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in TFE3-rearranged renal cell carcinoma.

Abstract Poster

Authors

null

Junjie Zhao

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Junjie Zhao , Yanfeng Tang , Xu Hu , Junru Chen , Haoyang Liu , Haolin Liu , Jiayu Liang , Xingming Zhang , Jinge Zhao , Pengfei Shen , Zhenhua Liu , Guangxi Sun , Hao Zeng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 429)

DOI

10.1200/JCO.2024.42.4_suppl.429

Abstract #

429

Poster Bd #

H11

Abstract Disclosures

Similar Posters

First Author: Marine Gross-Goupil

First Author: Patrick Joseph O'Shea

First Author: Amishi Yogesh Shah

First Author: Amishi Yogesh Shah